FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3191861283> ?p ?o ?g. }

• W3191861283 endingPage "1236" @default.
• W3191861283 startingPage "1236" @default.
• W3191861283 abstract "Arteannuin B (AB) has been found to demonstrate obvious anti-tumor activity. However, AB is not available for clinical use due to its very low solubility and very short half-life. This study aimed to develop AB long sustained-release microspheres (ABMs) to improve the feasibility of clinical applications. Firstly, AB-polylactic-co-glycolic acid (PLGA) microspheres were prepared by a single emulsification method. In vitro characterization studies showed that ABMs had a low burst release and stable in vitro release for up to one week. The particle size of microspheres was 69.10 μm (D50). The drug loading is 37.8%, and the encapsulation rate is 85%. Moreover, molecular dynamics modeling was firstly used to simulate the preparation process of microspheres, which clearly indicated the molecular image of microspheres and provided in-depth insights for understanding several key preparation parameters. Next, in vivo pharmacokinetics (PK) study was carried out to evaluate its sustained release effect in Sprague-Dawley (SD) rats. Subsequently, the methyl thiazolyl tetrazolium (MTT) method with human lung cancer cells (A549) was used to evaluate the in vitro efficacy of ABMs, which showed the IC50 of ABMs (3.82 μM) to be lower than that of AB (16.03 μM) at day four. Finally, in vivo anti-tumor activity and basic toxicity studies were performed on BALB/c nude mice by subcutaneous injection once a week, four times in total. The relative tumor proliferation rate T/C of AMBs was lower than 40% and lasted for 21 days after administration. The organ index, organ staining, and tumor cell staining indicated the excellent safety of ABMs than Cis-platinum. In summary, the ABMs were successfully developed and evaluated with a low burst release and a stable release within a week. Molecular dynamics modeling was firstly applied to investigate the molecular mechanism of the microsphere preparation. Moreover, the ABMs possess excellent in vitro and in vivo anti-tumor activity and low toxicity, showing great potential for clinical applications." @default.
• W3191861283 created "2021-08-16" @default.
• W3191861283 creator A5006408483 @default.
• W3191861283 creator A5013539817 @default.
• W3191861283 creator A5015083252 @default.
• W3191861283 creator A5019278885 @default.
• W3191861283 creator A5021711468 @default.
• W3191861283 creator A5024615233 @default.
• W3191861283 creator A5027756395 @default.
• W3191861283 creator A5048612717 @default.
• W3191861283 creator A5086045569 @default.
• W3191861283 creator A5088548138 @default.
• W3191861283 date "2021-08-11" @default.
• W3191861283 modified "2023-09-29" @default.
• W3191861283 title "Development of Arteannuin B Sustained-Release Microspheres for Anti-Tumor Therapy by Integrated Experimental and Molecular Modeling Approaches" @default.
• W3191861283 cites W1975738378 @default.
• W3191861283 cites W1996773895 @default.
• W3191861283 cites W2000279958 @default.
• W3191861283 cites W2003949305 @default.
• W3191861283 cites W2004482027 @default.
• W3191861283 cites W2020438942 @default.
• W3191861283 cites W2025626337 @default.
• W3191861283 cites W2025910698 @default.
• W3191861283 cites W2029667189 @default.
• W3191861283 cites W2044338930 @default.
• W3191861283 cites W2048652034 @default.
• W3191861283 cites W2055517049 @default.
• W3191861283 cites W2067476722 @default.
• W3191861283 cites W2070415161 @default.
• W3191861283 cites W2084515036 @default.
• W3191861283 cites W2105852378 @default.
• W3191861283 cites W2118233996 @default.
• W3191861283 cites W2121496050 @default.
• W3191861283 cites W2134126803 @default.
• W3191861283 cites W2147993766 @default.
• W3191861283 cites W2150131515 @default.
• W3191861283 cites W2166363384 @default.
• W3191861283 cites W2239579510 @default.
• W3191861283 cites W2332712348 @default.
• W3191861283 cites W2372630946 @default.
• W3191861283 cites W2561001592 @default.
• W3191861283 cites W2611172138 @default.
• W3191861283 cites W2735334137 @default.
• W3191861283 cites W2744934052 @default.
• W3191861283 cites W2784261849 @default.
• W3191861283 cites W2898616633 @default.
• W3191861283 cites W2910745285 @default.
• W3191861283 cites W2919942359 @default.
• W3191861283 cites W2944375531 @default.
• W3191861283 cites W2947994919 @default.
• W3191861283 cites W2967436081 @default.
• W3191861283 cites W2988014941 @default.
• W3191861283 cites W2998743749 @default.
• W3191861283 cites W3011143677 @default.
• W3191861283 cites W3021856719 @default.
• W3191861283 cites W3086057753 @default.
• W3191861283 cites W3112858196 @default.
• W3191861283 cites W3125203180 @default.
• W3191861283 cites W3169493564 @default.
• W3191861283 cites W4248425431 @default.
• W3191861283 doi "https://doi.org/10.3390/pharmaceutics13081236" @default.
• W3191861283 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8399913" @default.
• W3191861283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34452197" @default.
• W3191861283 hasPublicationYear "2021" @default.
• W3191861283 type Work @default.
• W3191861283 sameAs 3191861283 @default.
• W3191861283 citedByCount "2" @default.
• W3191861283 countsByYear W31918612832022 @default.
• W3191861283 countsByYear W31918612832023 @default.
• W3191861283 crossrefType "journal-article" @default.
• W3191861283 hasAuthorship W3191861283A5006408483 @default.
• W3191861283 hasAuthorship W3191861283A5013539817 @default.
• W3191861283 hasAuthorship W3191861283A5015083252 @default.
• W3191861283 hasAuthorship W3191861283A5019278885 @default.
• W3191861283 hasAuthorship W3191861283A5021711468 @default.
• W3191861283 hasAuthorship W3191861283A5024615233 @default.
• W3191861283 hasAuthorship W3191861283A5027756395 @default.
• W3191861283 hasAuthorship W3191861283A5048612717 @default.
• W3191861283 hasAuthorship W3191861283A5086045569 @default.
• W3191861283 hasAuthorship W3191861283A5088548138 @default.
• W3191861283 hasBestOaLocation W31918612831 @default.
• W3191861283 hasConcept C112705442 @default.
• W3191861283 hasConcept C127413603 @default.
• W3191861283 hasConcept C147789679 @default.
• W3191861283 hasConcept C150903083 @default.
• W3191861283 hasConcept C178790620 @default.
• W3191861283 hasConcept C185592680 @default.
• W3191861283 hasConcept C187530423 @default.
• W3191861283 hasConcept C189942447 @default.
• W3191861283 hasConcept C202751555 @default.
• W3191861283 hasConcept C207001950 @default.
• W3191861283 hasConcept C2780165375 @default.
• W3191861283 hasConcept C2781162966 @default.
• W3191861283 hasConcept C42360764 @default.
• W3191861283 hasConcept C521977710 @default.
• W3191861283 hasConcept C55493867 @default.
• W3191861283 hasConcept C71924100 @default.
• W3191861283 hasConcept C86803240 @default.

• next